The in vitro antifungal susceptibility of 77 isolates belonging to different clinically relevant species of Aspergillus section Flavi, including those of different phylogenetic clades of A. flavus, was tested for nine antifungal agents using a microdilution reference method (CLSI, M38-A2). Terbinafine and the echinocandins demonstrated lower MICs/MECs for all species evaluated, followed by posaconazole. Amphotericin B showed MICs > 2 g/ml for 38 (49.4%) of the 77 isolates tested.
I nvasive aspergillosis is the most common cause of mortality resulting from infection by filamentous fungi in leukemic patients and hematopoietic stem cell transplant (HSCT) recipients worldwide (1) . After Aspergillus fumigatus, A. flavus is the leading cause of invasive and noninvasive aspergillosis, particularly in infections of the respiratory tract, skin, mucosae, and eyes (2, 3) . In contrast to A. fumigatus, A. flavus rarely causes invasive pneumonia and systemic infections in immunocompetent hosts (4) . Voriconazole (VRC) is currently the drug of choice for the treatment of aspergillosis, although lipid formulations of amphotericin B (AMB), posaconazole (PSC), and caspofungin (CFG) have also been recommended to treat invasive aspergillosis refractory to or intolerant to other therapies (5) . Human infections by A. flavus usually respond to treatment with AMB, VRC, and itraconazole (ITC), although failures of these drugs in cases of aspergillosis have already been reported (6) (7) (8) (3, (9) (10) (11) (12) . The high number of species of such a section that are potentially pathogenic for humans and their morphological similarity make it difficult to ascertain the clinical and epidemiological peculiarities of the infections they cause. In addition, cryptic species have been described within the taxon A. flavus, the most frequent infecting species (13, 14) . Using molecular tools, we recently identified three phylogenetic species of A. flavus causing infections in humans (14) . Considering that the antifungal susceptibility profiles of the members of the section Flavi are not completely known, in the present study, we evaluated the in vitro activity of nine antifungal drugs against 77 isolates representative of clinically relevant species, including A. flavus (belonging to our clades I, II, and III) (14) , A. oryzae (belonging to our A. oryzae group) (14) , A. parasiticus, A. tamarii, and A. novoparasiticus ( Table 1) .
The isolates were cultured on potato dextrose agar (PDA; Difco Laboratories, Detroit, MI) and incubated at 25°C for 7 days to prepare the fungal inocula. Paecilomyces variotii ATCC 36257, Candida parapsilosis ATCC 22019, and Candida krusei ATCC 6258 were included as control organisms. The isolates were previously identified by sequencing the acetamidase (amdS) and Omethyltransferase (omtA) genes and the internal transcribed spacer (ITS) region of ribosomal DNA (rDNA) (14, 15) . Antifungal susceptibility testing was performed according to the Clinical and Laboratory Standards Institute (CLSI) M38-A2 protocol (16) . Briefly, 100-l culture preparations in RPMI 1640 with 2% glucose were inoculated into the flat-bottom wells of 96-well microtiter plates containing 100 l of the drug dilutions. The final inoculum concentration ranged from 0.4 ϫ 10 4 to 5 ϫ 10 4 CFU/ml. The drugs tested were provided by the manufacturers as pure powders and included the following: terbinafine (TRB), ITC, VRC, PSC, AMB, anidulafungin (AFG), micafungin (MFG), CFG, and 5-fluorocytosine (5FC). The MIC endpoints for the triazoles and AMB were defined as the lowest concentration that resulted in complete growth inhibition, while that of 5FC was defined as the lowest concentration that caused 50% growth inhibition. For the echinocandins, we applied the minimum effective concentration (MEC) endpoints, which were defined as the minimal antifungal concentration that caused visible morphological alterations of the hyphae. Tests were performed in duplicate, and when the results did not concur, the test was repeated and the mode of the MICs and MECs was considered.
The results are shown in Table 1 . In general, TRB and the echinocandins showed the lowest MICs/MECs for all species tested. Terbinafine showed a total geometric mean (GM) MIC of 0.03 g/ml, while AFG and MFG showed a total GM MEC of 0.03 g/ml. For CFG, the total GM MEC was 0.07 g/ml. Posaconazole exhibited the lowest GM MIC among the azoles tested (0.35 g/ ml). Voriconazole and ITC showed a total GM MIC of 0.60 g/ml. The three clades of A. flavus exhibited similar in vitro susceptibilities to all drugs tested. Despite some numerical differences that were observed among the MICs obtained with different triazoles, the GM MICs were quite similar and mostly within double dilutions, demonstrating the expected variability for the method. Regarding the other drugs evaluated, AMB exhibited MICs Ն 2 for 38 (49.4%) of the 77 isolates tested, and 5FC showed poor in vitro activity against all species tested (GM MIC ϭ 51.56 g/ml). ITC, The treatment of invasive aspergillosis is a challenge due to the diagnostic difficulty, the severity of the clinical conditions of the patients, and the limited number of antifungal drugs available (8) .
Little is known about the prevalence of A. flavus and cryptic species in clinical samples or their susceptibility to antifungal drugs. One of the most interesting findings of this study was the demonstration that echinocandins generally exhibited higher in vitro activity than triazoles and AMB against all species. In addition, no differences in susceptibility were observed within the three A. flavus clades. Otherwise, A. tamarii appears to be less susceptible to azoles than other species of the section. Aspergillus tamarii has been primarily described to cause sinusitis, keratitis, and onychomycosis (11, 17, 18) . In the case of azoles, the MICs of ITC and VRC for all isolates were higher than that of PSC, which is in agreement with other studies (19) (20) (21) . Amphotericin B appears to have limited activity against most species of the section Flavi. In general, the AMB MIC values were at least 2-fold higher than those obtained with isolates of the section Fumigati (22, 23) . Lass-Flörl et al. (24) correlated the in vitro antifungal susceptibility of 12 A. flavus strains isolated from bone marrow transplant recipients with their clinical outcome. Only the four patients infected with susceptible isolates (AMB MIC Ͻ 2 g/ml; n ϭ 4) survived, while those with resistant isolates (AMB MIC Ն 2 g/ml; n ϭ 8) died. Despite showing excellent in vitro activity against some strains of Aspergillus spp., the therapeutic efficacy of TRB in the management of nondermatophytic mold infections is still unclear at present (25) .
In summary, there is a great diversity of species belonging to the section Flavi that cause infections in humans. We emphasize the importance of using molecular methods to accurately identify Aspergillus at the species level because different species may vary in terms of susceptibility to antifungal agents. a Data for clades I, II, and III and the A. oryzae group are from Gonçalves et al. (14) . GM, geometric mean. b AMB, amphotericin B; ITC, itraconazole; VRC, voriconazole; PSC, posaconazole; TR, terbinafine; 5FC, 5-fluorocytosine; CFG, caspofungin; AFG, anidulafungin; MFG, micafungin. c MIC 50 , concentration at which 50% of the isolates were inhibited; MIC 90 , concentration at which 90% of the isolates were inhibited. d MEC 50 , concentration at which 50% of the isolates showed morphological changes in the growing hyphae; MEC 90 , concentration at which 90% of the isolates showed morphological changes in the growing hyphae.
